Kane Biotech Secures NRC Funding for Wound Care Innovation

Kane Biotech Inc. announced that it has secured up to $75,000 in funding and advisory services through the National Research Council of Canada’s Industrial Research Assistance Program (NRC IRAP). The funding will support a collaborative research and development project with one of the world’s largest wound care companies to develop a Proof-of-Concept for its DispersinB® Wound Gel over a six-month period. CEO Marc Edwards highlighted the potential of DispersinB® as a disruptive technology attracting industry attention. Additionally, Kane recently received up to $200,000 from NRC IRAP for further development of three products based on its revyve™ Antimicrobial Wound Gel.

Edwards emphasized the significance of these NRC IRAP contributions in advancing Kane Biotech’s wound care technologies, boosting financial support, and driving innovation through collaborations with industry leaders. These projects aim to create new breakthroughs in the wound care sector, enhancing both DispersinB® and revyve™ technologies.